Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
Historical Events
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Lymphocytic Leukemia, Chronic
Clinical Trial
Last updated: 12/4/2025
MRTX
Mirati Therapeutics, Inc.
